Search Results for: THERAPEUTIC FOCUS Adenosine Receptors The
Articles
May 4, 2015
THERAPEUTIC FOCUS - Adenosine Receptors – The Promise of A3AR Research May 4, 2015
Pnina Fishman, PhD, reports that the A3AR adenosine receptor, expressed in the lungs, liver, brain, aorta, testis, and heart, may hold promise as both a therapeutic target and as a biological predictive marker.
January 18, 2023
Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate Novel Oral Immune Response Modifier in Combination with KEYTRUDA January 18, 2023
Teon Therapeutics (Teon) recently announced it has entered into the clinical trial collaboration agreement with Merck for the combination arm of Teon’s ongoing, two-armed, open-label, dose….
November 1, 2022
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of a Novel Oral Immune Checkpoint Inhibitor November 1, 2022
Teon Therapeutics recently announced the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and...
June 2, 2022
Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor June 2, 2022
Teon Therapeutics recently announced the acceptance by the US FDA of Teon’s Investigational New Drug (IND) application for the study of TT-816. TT-816 is a novel, oral cannabinoid CB2 receptor….
June 9, 2021
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of its Adenosine A2A Receptor Antagonist June 9, 2021
iTeos Therapeutics, Inc. recently announced new clinical data from its ongoing Phase 1/2a clinical trial of inupadenant (EOS-850), a next-generation...
